Share

George Church

Ph.D.

Director, NHGRI Center for Excellence in Genomic Science

Robert Winthrop Professor of Genetics, Harvard Medical School

Professor of Health Sciences and Technology, Harvard and MIT

Founding Core Faculty and Lead, Wyss Institute, Harvard University

Dr. Church  is Professor of Genetics at Harvard Medical School and Professor of Health Sciences and Technology at Harvard and the Massachusetts Institute of Technology (MIT), a founding member of the Wyss Institute, and Director of PersonalGenomes.org, the world’s only open-access information on human genomic, environmental, and trait data. Dr. Church is Director of IARPA & NIH BRAIN Projects, and Director of the National Institutes of Health Center for Excellence in Genomic Science. 

Dr. Church is known for pioneering the fields of personal genomics and synthetic biology. He developed the first methods for the first genome sequence & dramatic cost reductions since then (down from $3 billion to $600), contributing to nearly all “next generation sequencing” methods and companies. His team invented CRISPR for human stem cell genome editing and other synthetic biology technologies and applications – including new ways to create organs for transplantation, gene therapies for aging reversal, and gene drives to eliminate Lyme Disease and Malaria. He has co-authored more than 590 papers and 155 patent publications, and one book, “Regenesis”.

He has received numerous awards including the 2011 Bower Award and Prize for Achievement in Science from the Franklin Institute, the Time 100, and election to the National Academy of Sciences and Engineering.

George Church

Ph.D.

Director, NHGRI Center for Excellence in Genomic Science

Robert Winthrop Professor of Genetics, Harvard Medical School

Professor of Health Sciences and Technology, Harvard and MIT

Founding Core Faculty and Lead, Wyss Institute, Harvard University

Dr. Church  is Professor of Genetics at Harvard Medical School and Professor of Health Sciences and Technology at Harvard and the Massachusetts Institute of Technology (MIT), a founding member of the Wyss Institute, and Director of PersonalGenomes.org, the world’s only open-access information on human genomic, environmental, and trait data. Dr. Church is Director of IARPA & NIH BRAIN Projects, and Director of the National Institutes of Health Center for Excellence in Genomic Science. 

Dr. Church is known for pioneering the fields of personal genomics and synthetic biology. He developed the first methods for the first genome sequence & dramatic cost reductions since then (down from $3 billion to $600), contributing to nearly all “next generation sequencing” methods and companies. His team invented CRISPR for human stem cell genome editing and other synthetic biology technologies and applications – including new ways to create organs for transplantation, gene therapies for aging reversal, and gene drives to eliminate Lyme Disease and Malaria. He has co-authored more than 590 papers and 155 patent publications, and one book, “Regenesis”.

He has received numerous awards including the 2011 Bower Award and Prize for Achievement in Science from the Franklin Institute, the Time 100, and election to the National Academy of Sciences and Engineering.

Recent Publications

Identification of candidate markers for the isolation of neuron-specific extracellular vesicles

Published On 2026 Oct 23

Journal article

Extracellular vesicles (EVs) are present in biofluids and may be useful biomarkers to non-invasively monitor brain cells, but isolating cell type-specific EVs remains challenging. Here we introduce an approach to immuno-isolate EVs from neurons and glia based on protein surface markers. We first selected transmembrane proteins suitable as cell type-specific EV markers based on gene expression and EV proteomic data. We developed a high-purity EV isolation method and cataloged the proteins present...


Transcriptomic reprogramming screen identifies SRSF1 as a regulator of aging

Published On 2026 Oct 14

Journal article

Aging is characterized by progressive functional decline accompanied by distinct transcriptomic and epigenetic alterations. Although partial reprogramming via Yamanaka factors can reverse these signatures and improve cell function, toxicity and efficacy concerns limit their in vivo application, necessitating alternative geroprotective interventions. Here we develop an interpretable transcriptomic age predictor in human fibroblasts and perform a cDNA overexpression screen to identify factors that...